Transaction DateRecipientSharesTypePriceValue
9th September 2020Huw M. Nash17,201Open or private sale$30.00$516,030.00
9th September 2020Group, Llc Redmile8,650Open or private purchase$51.85$448,523.26
9th September 2020Group, Llc Redmile14,610Open or private purchase$52.96$773,811.35
9th September 2020Huw M. Nash17,201Exercise of derivative$2.19$37,670.19
8th September 2020Huw M. Nash30,718Open or private sale$30.00$921,540.00
8th September 2020Huw M. Nash30,718Exercise of derivative$2.19$67,272.42
8th September 2020Group, Llc Redmile47,113Open or private purchase$49.91$2,351,504.06
4th September 2020Group, Llc Redmile74,433Open or private purchase$50.28$3,742,186.06
3rd September 2020Group, Llc Redmile74,253Open or private purchase$48.69$3,615,207.79
2nd September 2020Group, Llc Redmile19,173Open or private purchase$46.76$896,592.75
Stoke Therapeutics
Stoke Therapeutics logo

Stoke Therapeutics, Inc. engages in the research and development of treatments for genetic diseases. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Ticker: STOK
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1623526
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags